Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients. The drug works by targeting the BCR‑ABL protein that drives malignant cell growth.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted oral therapy that inhibits the BCR‑ABL tyrosine‑kinase pathway in specific leukemias.

- Chronic myeloid leukemia (CML) in chronic phase: helps achieve and maintain cytogenetic and molecular remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): used in combination with chemotherapy to improve survival outcomes.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - QT interval prolongation: risk of cardiac arrhythmia. - Elevated pancreatic enzymes: may indicate pancreatitis. - Severe hepatotoxicity: marked increase in liver transaminases.

Patients receiving Nilotinib should be monitored for specific safety concerns.

- Cardiac monitoring: assess QT interval before and during therapy. - Hepatic function: check liver enzymes regularly. - Metabolic control: monitor blood glucose and lipid levels. - Drug interactions: avoid strong CYP3A4 inhibitors and QT‑prolonging agents. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, fluoroquinolones): raise risk of cardiac arrhythmia. - Antacids or proton‑pump inhibitors that raise gastric pH: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may require dose adjustment. - Warfarin: monitor INR as nilotinib can affect anticoagulation control.